STERIS plc
232.15USD
-0.0700 (-0.03%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on STE.
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
Do analysts expect earnings and revenue to keep growing?
1 of 6 checks could not be assessed (there is no analyst coverage stored).
Has the business grown and earned good returns on its filed numbers?
Can the balance sheet carry its debt?
Is the dividend decent, covered and steady?
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
P/E 28.4 against a peer median of 29.4 (14 USD companies in Medical Devices).
Passed
PEG ratio
The PEG ratio is positive and at most 1.5.
PEG 1.79.
Did not pass
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 14.8 against a peer median of 17.5 (15 USD companies in Medical Devices).
Passed
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Price/book 3.14 against a peer median of 4.87 (20 USD companies in Medical Devices).
Passed
Statements: SEC filings, newest period 06/2026.
Peers: P/E against 14 USD companies in Medical Devices; EV/EBITDA against 15 USD companies in Medical Devices; price/book against 20 USD companies in Medical Devices.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 4.1% against a 4.5% risk-free rate.
Did not pass
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target above the last close by 12.3% (7 analysts).
Did not pass
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: consensus up 10.1% (8 analysts).
Passed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: consensus up 10.1% (8 analysts).
Passed
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 6.7% (7 analysts).
Passed
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus up 7.5% (7 analysts).
Passed
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 7.3% on a year earlier.
Did not pass
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income grew 14.5% a year, FY2021 to FY2026.
Passed
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income up 24.5% (twelve months to 06/2026).
Passed
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 13.8% a year, FY2021 to FY2026.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity 11.4%: twelve-month net income over the average equity.
Did not pass
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets 7.6%: twelve-month net income over the average assets.
Passed
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 1.9x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 1.1x the liabilities due after a year.
Passed
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Total debt is 26% of equity.
Passed
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt is 0.9x EBITDA.
Passed
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
Operating income covers interest 18.8x.
Passed
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 68.0% of total debt.
Passed
Dividend yield
The dividend yield is at least 2%.
Dividend yield 1.11%.
Did not pass
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
Dividends paid were 31% of net income.
Passed
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
Free cash flow covers dividends 3.7x.
Passed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
A dividend was paid in all 8 fiscal years, FY2019 to FY2026.
Passed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
No fall of more than 20% between fiscal years, FY2019 to FY2026.
Passed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
Total dividends grew 11.6% a year, FY2019 to FY2026.
Passed